Adrenal hemorrhage and non-ST elevation myocardial infarction: an antiphospholipid syndrome dilemma

0Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

Antiphospholipid syndrome (APS) can affect different organ systems, including the heart and adrenal glands. Despite being known for its prothrombotic characteristics, APS can have serious bleeding complications. Occasionally, thrombotic and bleeding episodes can present simultaneously in an APS patient. Whenever these events co-occur, resuming anticoagulation becomes a topic of debate. As such, we present the case of a 43-year-old male with triple positive antiphospholipid antibodies, indicating APS, who presented with chest pain. Anticoagulants were switched one month before presentation from warfarin to a direct oral anticoagulant, rivaroxaban. Non-ST elevation myocardial infarction, as well as new-onset left-sided adrenal hemorrhage, were diagnosed. The patient developed adrenal insufficiency; therefore, corticosteroids were administered, and warfarin was resumed to prevent further thrombotic episodes.

Cite

CITATION STYLE

APA

Hasbani, G. E., Morel, M. D. P., Tandoh, B., Vargas, J. F., & Crusio, R. (2023). Adrenal hemorrhage and non-ST elevation myocardial infarction: an antiphospholipid syndrome dilemma. Reumatismo, 75(3), 138–143. https://doi.org/10.4081/reumatismo.2023.1584

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free